Toll Free: 1-888-928-9744

Gastroparesis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gastroparesis - Pipeline Review, H1 2015


Global Markets Direct's, 'Gastroparesis - Pipeline Review, H1 2015', provides an overview of the Gastroparesis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Gastroparesis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroparesis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastroparesis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroparesis - Overview 7
Pipeline Products for Gastroparesis - Comparative Analysis 8
Gastroparesis - Therapeutics under Development by Companies 9
Gastroparesis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Gastroparesis - Products under Development by Companies 13
Gastroparesis - Companies Involved in Therapeutics Development 14
GlaxoSmithKline plc 14
RaQualia Pharma Inc. 15
Gastroparesis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 23
camicinal - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ETX-101 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NG-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RQ-00000010 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RQ-00201894 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
velusetrag - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gastroparesis - Recent Pipeline Updates 30
Gastroparesis - Dormant Projects 33
Gastroparesis - Product Development Milestones 34
Featured News & Press Releases 34
Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA 34
Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis 34
Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37
List of Tables
Number of Products under Development for Gastroparesis, H1 2015 7
Number of Products under Development for Gastroparesis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Gastroparesis - Pipeline by GlaxoSmithKline plc, H1 2015 14
Gastroparesis - Pipeline by RaQualia Pharma Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 18
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 21
Number of Products by Stage and Molecule Type, H1 2015 22
Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2015 30
Gastroparesis - Dormant Projects, H1 2015 33 

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.